Skip to main content

Compare Stocks

Date Range: 

 Champions OncologyBiomXCheckmate PharmaceuticalsX4 PharmaceuticalsERYTECH Pharma
SymbolNASDAQ:CSBRNYSEMKT:PHGENASDAQ:CMPINASDAQ:XFORNASDAQ:ERYP
Price Information
Current Price$9.55$5.68$6.74$7.63$6.87
52 Week RangeBuyBuyBuyBuyN/A
MarketRank™
Overall Score1.80.62.01.80.5
Analysis Score3.50.03.43.50.0
Community Score2.22.92.52.82.1
Dividend Score0.00.00.00.00.0
Ownership Score1.70.03.31.70.0
Earnings & Valuation Score1.90.00.61.30.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyN/A
Consensus Price Target$16.00$25.00$24.75$18.00N/A
% Upside from Price Target67.54% upside340.14% upside267.21% upside135.91% upsideN/A
Trade Information
Market Cap$127.88 million$132.06 million$145.76 million$132.64 million$148.59 million
Beta1.20.48N/A0.532.73
Average Volume30,63725,23647,491113,62319,774
Sales & Book Value
Annual Revenue$32.12 millionN/AN/AN/AN/A
Price / Sales3.98N/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.45 per share$3.83 per shareN/A$10.37 per share$5.34 per share
Price / Book21.22N/AN/AN/AN/A
Profitability
Net Income$-1,980,000.00$-20,560,000.00$-28,290,000.00$-52,810,000.00$-70,180,000.00
EPS($0.17)($3.66)N/A($4.63)($3.92)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E Ratio63.67N/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-4.18%N/AN/AN/AN/A
Return on Equity (ROE)-29.93%-39.95%N/A-47.06%N/A
Return on Assets (ROA)-7.41%-36.65%-57.12%-35.89%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.24%0.09%
Current Ratio1.18%13.87%16.26%10.19%2.39%
Quick Ratio1.18%13.87%16.26%10.19%2.37%
Ownership Information
Institutional Ownership Percentage52.84%26.78%75.64%67.76%6.47%
Insider Ownership Percentage46.80%23.20%N/A4.90%N/A
Miscellaneous
Employees143952272206
Shares Outstanding13.39 million23.25 million21.63 million17.38 million21.62 million
Next Earnings Date7/26/2021 (Estimated)N/A9/17/2021 (Estimated)7/29/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2021 Results - Earnings Call TranscriptERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 12:55 PM
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2021Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2021
finance.yahoo.com - May 7 at 3:18 PM
Erytech Pharma ADR Earnings Beat, Revenue Misses In Q1Erytech Pharma ADR Earnings Beat, Revenue Misses In Q1
investing.com - May 4 at 11:50 PM
ERYTECH Provides Business Update and  Reports Financial Results for the First Quarter of 2021ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021
finance.yahoo.com - May 4 at 6:39 PM
ERYTECH Pharma S.A. (NASDAQ:ERYP) Expected to Announce Earnings of -$0.89 Per ShareERYTECH Pharma S.A. (NASDAQ:ERYP) Expected to Announce Earnings of -$0.89 Per Share
americanbankingnews.com - May 2 at 12:38 PM
ERYTECH Pharma (ERYP) Set to Announce Earnings on TuesdayERYTECH Pharma (ERYP) Set to Announce Earnings on Tuesday
americanbankingnews.com - April 29 at 8:52 AM
ERYTECH Pharma S.A. (NASDAQ:ERYP) Short Interest UpdateERYTECH Pharma S.A. (NASDAQ:ERYP) Short Interest Update
americanbankingnews.com - April 29 at 7:48 AM
ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 ...ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 ...
apnews.com - April 28 at 11:24 PM
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharmas EpidiolexThe Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
markets.businessinsider.com - April 20 at 8:31 AM
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALLERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
finance.yahoo.com - April 20 at 8:31 AM
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of ...ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of ...
apnews.com - April 19 at 9:43 AM
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic CancerERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
finance.yahoo.com - April 19 at 9:43 AM
Erytech Pharma SA ADR (ERYP)Erytech Pharma SA ADR (ERYP)
investing.com - April 18 at 6:39 PM
ERYTECH to Participate in Upcoming Virtual Investor Conferences in AprilERYTECH to Participate in Upcoming Virtual Investor Conferences in April
finance.yahoo.com - April 7 at 5:59 PM
Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2021Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2021
finance.yahoo.com - April 7 at 12:58 PM
ERYTECH Pharma S.A. (ERYP.PA)ERYTECH Pharma S.A. (ERYP.PA)
au.finance.yahoo.com - March 18 at 8:39 AM
Erytech Pharma S.A.: ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020Erytech Pharma S.A.: ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020
bloomberg.com - March 10 at 6:30 PM
ERYTECH Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-FERYTECH Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
finance.yahoo.com - March 9 at 5:07 PM
Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2021Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2021
finance.yahoo.com - March 5 at 1:43 PM
ERYTECH Pharma (ERYP) Sees Hammer Chart Pattern: Time to Buy?ERYTECH Pharma (ERYP) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - March 5 at 8:43 AM
ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business UpdateERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update
finance.yahoo.com - March 4 at 8:33 PM
Erytech Pharma S.A.: ERYTECH to Participate in Upcoming Virtual Investor Conferences in MarchErytech Pharma S.A.: ERYTECH to Participate in Upcoming Virtual Investor Conferences in March
bloomberg.com - February 26 at 9:29 AM
ERYTECH to Participate in Upcoming Virtual Investor Conferences in MarchERYTECH to Participate in Upcoming Virtual Investor Conferences in March
finance.yahoo.com - February 24 at 8:14 PM
ERYTECH to Present at the 2021 BIO CEO & Investor ConferenceERYTECH to Present at the 2021 BIO CEO & Investor Conference
finance.yahoo.com - February 10 at 8:26 PM
Erytech Pharma S.A.: ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final AnalysisErytech Pharma S.A.: ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis
bloomberg.com - February 9 at 10:42 PM
DateCompanyBrokerageAction
3/22/2021Champions OncologyRoth CapitalBoost Price Target
11/27/2019Champions OncologyBenchmarkInitiated Coverage
7/24/2019Champions OncologyJanney Montgomery ScottDowngrade
2/27/2019Champions OncologyNational SecuritiesInitiated Coverage
7/17/2018Champions OncologyCraig HallumInitiated Coverage
4/21/2021BiomXLADENBURG THALM/SH SHInitiated Coverage
12/7/2020BiomXHC WainwrightReiterated Rating
1/9/2020BiomXCantor FitzgeraldReiterated Rating
3/19/2021Checkmate PharmaceuticalsJefferies Financial GroupLower Price Target
9/1/2020Checkmate PharmaceuticalsBank of AmericaInitiated Coverage
9/1/2020Checkmate PharmaceuticalsBMO Capital MarketsInitiated Coverage
9/1/2020Checkmate PharmaceuticalsBTIG ResearchInitiated Coverage
3/22/2021X4 PharmaceuticalsOppenheimerReiterated Rating
12/17/2020X4 PharmaceuticalsBrookline Capital ManagementInitiated Coverage
11/30/2020X4 PharmaceuticalsB. RileyReiterated Rating
11/9/2020X4 PharmaceuticalsCanaccord GenuityLower Price Target
3/26/2020X4 PharmaceuticalsCitigroupLower Price Target
3/12/2020X4 PharmaceuticalsCowenReiterated Rating
6/7/2019X4 PharmaceuticalsStifel NicolausInitiated Coverage
9/5/2019ERYTECH PharmaJMP SecuritiesReiterated Rating
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.